Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms

Nilda Gonzalez-Roibon, Sheila F. Faraj, Enrico Munari, Stephania M. Bezerra, Roula Albadine, Rajni Sharma, Pedram Argani, Mohamad E Allaf, George J. Netto

Research output: Contribution to journalArticle

Abstract

Transcription factor GATA binding protein 3 (GATA3) has been suggested as a marker of urothelial carcinoma of the bladder and upper urinary tract. Its expression in primary and metastatic renal tumors has not been fully determined. We evaluated GATA3 expression in 47 oncocytomas, 196 primary renal cell carcinomas (RCCs) (71 clear cell, 53 papillary, 21 Xp11.2, 33 chromophobe RCCs, and 18 collecting duct carcinomas [CDC]), and 43 unrelated metastatic RCCs (41 clear cell and 2 Xp11.2 RCC). GATA3 nuclear expression was evaluated in tissue microarrays built from archival tissues using immunohistochemistry. Intensity (0 to 3+) and extent (percentage) of expression were assessed. Several cutoff values (>0%, >5%, and >10%) were evaluated to indicate GATA3 positivity. Among oncocytomas, 9 (19%) of 47 had some degree of nuclear GATA3 expression with median extent of 0% (0%-100%). When using either 5% or 10% cutoff values, 5 (11%) of 47 oncocytomas were positive. In primary RCCs, 6 (3%) of 196 had some degree of nuclear expression with a median extent of 0% (0%-100%). When using either 5% or 10% cutoff values, 2 cases remained positive (1%) (Xp11.2 and CDC). All metastatic RCCs were negative. We found an overall lack of GATA3 expression in primary and metastatic RCCs. GATA3 is expressed in a minority of oncocytomas, Xp11.2-RCC, and CDC. Given GATA3 positivity in upper urinary tract urothelial carcinoma, our findings support a role for GATA3 in the differential diagnosis of primary renal masses and a utility in the interrogation of metastatic tumors of unknown primary in the presence of a renal mass.

Original languageEnglish (US)
Pages (from-to)244-248
Number of pages5
JournalHuman Pathology
Volume45
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Carrier Proteins
Oxyphilic Adenoma
Urinary Tract
Kidney
Unknown Primary Neoplasms
GATA Transcription Factors
Carcinoma
Urinary Bladder
Differential Diagnosis
Immunohistochemistry

Keywords

  • GATA3
  • Immunohistochemistry
  • Oncocytoma
  • Renal cell carcinoma
  • Xp11 translocation carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Gonzalez-Roibon, N., Faraj, S. F., Munari, E., Bezerra, S. M., Albadine, R., Sharma, R., ... Netto, G. J. (2014). Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. Human Pathology, 45(2), 244-248. https://doi.org/10.1016/j.humpath.2013.08.020

Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. / Gonzalez-Roibon, Nilda; Faraj, Sheila F.; Munari, Enrico; Bezerra, Stephania M.; Albadine, Roula; Sharma, Rajni; Argani, Pedram; Allaf, Mohamad E; Netto, George J.

In: Human Pathology, Vol. 45, No. 2, 02.2014, p. 244-248.

Research output: Contribution to journalArticle

Gonzalez-Roibon, Nilda ; Faraj, Sheila F. ; Munari, Enrico ; Bezerra, Stephania M. ; Albadine, Roula ; Sharma, Rajni ; Argani, Pedram ; Allaf, Mohamad E ; Netto, George J. / Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. In: Human Pathology. 2014 ; Vol. 45, No. 2. pp. 244-248.
@article{35b9080c08284b348431c95685a0ade9,
title = "Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms",
abstract = "Transcription factor GATA binding protein 3 (GATA3) has been suggested as a marker of urothelial carcinoma of the bladder and upper urinary tract. Its expression in primary and metastatic renal tumors has not been fully determined. We evaluated GATA3 expression in 47 oncocytomas, 196 primary renal cell carcinomas (RCCs) (71 clear cell, 53 papillary, 21 Xp11.2, 33 chromophobe RCCs, and 18 collecting duct carcinomas [CDC]), and 43 unrelated metastatic RCCs (41 clear cell and 2 Xp11.2 RCC). GATA3 nuclear expression was evaluated in tissue microarrays built from archival tissues using immunohistochemistry. Intensity (0 to 3+) and extent (percentage) of expression were assessed. Several cutoff values (>0{\%}, >5{\%}, and >10{\%}) were evaluated to indicate GATA3 positivity. Among oncocytomas, 9 (19{\%}) of 47 had some degree of nuclear GATA3 expression with median extent of 0{\%} (0{\%}-100{\%}). When using either 5{\%} or 10{\%} cutoff values, 5 (11{\%}) of 47 oncocytomas were positive. In primary RCCs, 6 (3{\%}) of 196 had some degree of nuclear expression with a median extent of 0{\%} (0{\%}-100{\%}). When using either 5{\%} or 10{\%} cutoff values, 2 cases remained positive (1{\%}) (Xp11.2 and CDC). All metastatic RCCs were negative. We found an overall lack of GATA3 expression in primary and metastatic RCCs. GATA3 is expressed in a minority of oncocytomas, Xp11.2-RCC, and CDC. Given GATA3 positivity in upper urinary tract urothelial carcinoma, our findings support a role for GATA3 in the differential diagnosis of primary renal masses and a utility in the interrogation of metastatic tumors of unknown primary in the presence of a renal mass.",
keywords = "GATA3, Immunohistochemistry, Oncocytoma, Renal cell carcinoma, Xp11 translocation carcinoma",
author = "Nilda Gonzalez-Roibon and Faraj, {Sheila F.} and Enrico Munari and Bezerra, {Stephania M.} and Roula Albadine and Rajni Sharma and Pedram Argani and Allaf, {Mohamad E} and Netto, {George J.}",
year = "2014",
month = "2",
doi = "10.1016/j.humpath.2013.08.020",
language = "English (US)",
volume = "45",
pages = "244--248",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms

AU - Gonzalez-Roibon, Nilda

AU - Faraj, Sheila F.

AU - Munari, Enrico

AU - Bezerra, Stephania M.

AU - Albadine, Roula

AU - Sharma, Rajni

AU - Argani, Pedram

AU - Allaf, Mohamad E

AU - Netto, George J.

PY - 2014/2

Y1 - 2014/2

N2 - Transcription factor GATA binding protein 3 (GATA3) has been suggested as a marker of urothelial carcinoma of the bladder and upper urinary tract. Its expression in primary and metastatic renal tumors has not been fully determined. We evaluated GATA3 expression in 47 oncocytomas, 196 primary renal cell carcinomas (RCCs) (71 clear cell, 53 papillary, 21 Xp11.2, 33 chromophobe RCCs, and 18 collecting duct carcinomas [CDC]), and 43 unrelated metastatic RCCs (41 clear cell and 2 Xp11.2 RCC). GATA3 nuclear expression was evaluated in tissue microarrays built from archival tissues using immunohistochemistry. Intensity (0 to 3+) and extent (percentage) of expression were assessed. Several cutoff values (>0%, >5%, and >10%) were evaluated to indicate GATA3 positivity. Among oncocytomas, 9 (19%) of 47 had some degree of nuclear GATA3 expression with median extent of 0% (0%-100%). When using either 5% or 10% cutoff values, 5 (11%) of 47 oncocytomas were positive. In primary RCCs, 6 (3%) of 196 had some degree of nuclear expression with a median extent of 0% (0%-100%). When using either 5% or 10% cutoff values, 2 cases remained positive (1%) (Xp11.2 and CDC). All metastatic RCCs were negative. We found an overall lack of GATA3 expression in primary and metastatic RCCs. GATA3 is expressed in a minority of oncocytomas, Xp11.2-RCC, and CDC. Given GATA3 positivity in upper urinary tract urothelial carcinoma, our findings support a role for GATA3 in the differential diagnosis of primary renal masses and a utility in the interrogation of metastatic tumors of unknown primary in the presence of a renal mass.

AB - Transcription factor GATA binding protein 3 (GATA3) has been suggested as a marker of urothelial carcinoma of the bladder and upper urinary tract. Its expression in primary and metastatic renal tumors has not been fully determined. We evaluated GATA3 expression in 47 oncocytomas, 196 primary renal cell carcinomas (RCCs) (71 clear cell, 53 papillary, 21 Xp11.2, 33 chromophobe RCCs, and 18 collecting duct carcinomas [CDC]), and 43 unrelated metastatic RCCs (41 clear cell and 2 Xp11.2 RCC). GATA3 nuclear expression was evaluated in tissue microarrays built from archival tissues using immunohistochemistry. Intensity (0 to 3+) and extent (percentage) of expression were assessed. Several cutoff values (>0%, >5%, and >10%) were evaluated to indicate GATA3 positivity. Among oncocytomas, 9 (19%) of 47 had some degree of nuclear GATA3 expression with median extent of 0% (0%-100%). When using either 5% or 10% cutoff values, 5 (11%) of 47 oncocytomas were positive. In primary RCCs, 6 (3%) of 196 had some degree of nuclear expression with a median extent of 0% (0%-100%). When using either 5% or 10% cutoff values, 2 cases remained positive (1%) (Xp11.2 and CDC). All metastatic RCCs were negative. We found an overall lack of GATA3 expression in primary and metastatic RCCs. GATA3 is expressed in a minority of oncocytomas, Xp11.2-RCC, and CDC. Given GATA3 positivity in upper urinary tract urothelial carcinoma, our findings support a role for GATA3 in the differential diagnosis of primary renal masses and a utility in the interrogation of metastatic tumors of unknown primary in the presence of a renal mass.

KW - GATA3

KW - Immunohistochemistry

KW - Oncocytoma

KW - Renal cell carcinoma

KW - Xp11 translocation carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84892825178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892825178&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.08.020

DO - 10.1016/j.humpath.2013.08.020

M3 - Article

VL - 45

SP - 244

EP - 248

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 2

ER -